Elagolix

Drug Profile

Elagolix

Alternative Names: ABT-620; Elagolix sodium; NBI-56418

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer AbbVie; Neurocrine Biosciences
  • Class Antineoplastics; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Endometriosis; Uterine leiomyoma
  • Discontinued Benign prostatic hyperplasia; Prostate cancer

Most Recent Events

  • 12 Apr 2017 Updated efficacy and adverse events data from a phase IIb trial in Uterine leiomyoma released by AbbVie
  • 05 Apr 2017 Neurocrine Biosciences announces intention to submit NDA to US FDA for endometriosis in third quarter of 2017 (Neurocrine Biosciences form 10-K, filed in February 2017)
  • 01 Dec 2016 AbbVie completes a phase III trial in Endometriosis in USA, Argentina, Australia, Austria, Brazil, Czech Republic, Hungary, Italy, New Zealand, Poland, South Africa, Spain and United Kingdom (PO) (NCT01931670)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top